Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 7/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137861 | 0.96 | MAPT (0.34) | PYGBTLR4MAPTMAPK1LY96 | |
| SCHEMBL21137980 | 0.87 | PYGB (0.40) | PYGBTLR4MAPK1SLC5A1SLC5A2 | |
| SCHEMBL28855878 | 0.87 | PYGB (0.40) | PYGBTLR4MAPK1SLC5A1SLC5A2 | |
| SCHEMBL21138115 | 0.87 | MAPT (0.39) | PYGBTLR4MAPTMAPK1LY96 | |
| Hydrochloric Acid SCHEMBL29777443 | 0.86 | PYGB (0.39) | PYGBTLR4MAPK1SLC5A1SLC5A2 | |
| Hydrochloric Acid SCHEMBL21058387 | 0.86 | PYGB (0.39) | PYGBTLR4MAPK1SLC5A1SLC5A2 | |
| SCHEMBL21137982 | 0.83 | PYGB (0.37) | PYGBTLR4MAPTMAPK1LY96 | |
| SCHEMBL21137922 | 0.82 | MAPT (0.44) | PYGBTLR4MAPTLY96 | |
| SCHEMBL25835107 | 0.82 | MAPT (0.44) | PYGBTLR4MAPTLY96 | |
| SCHEMBL21137923 | 0.80 | TLR4 (0.48) | TLR4MAPTLY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885TLR4 896/4885MAPT 2761/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885TLR4 896/4885MAPT 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.